Biosimilars: Patient and physician acceptability is the fifth hurdle to market competition

Alan Lyles

Research output: Contribution to journalLetter

Abstract

Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.

Original languageEnglish (US)
Pages (from-to)6-7
Number of pages2
JournalGaBI Journal
Volume4
Issue number1
DOIs
StatePublished - 2015
Externally publishedYes

Keywords

  • Acceptability
  • Biologicals
  • Biosimilars
  • Interchangeability
  • Pricing

ASJC Scopus subject areas

  • Pharmacy
  • Drug guides

Fingerprint Dive into the research topics of 'Biosimilars: Patient and physician acceptability is the fifth hurdle to market competition'. Together they form a unique fingerprint.

Cite this